- On December 27, 2022, Zerenia
(Khiron´s wholly owned medical cannabis clinic network) signed a
contract with CAPITAL SALUD EPS, Colombia´s largest public
insurance company, under which Zerenia will provide medical
cannabis services and products to its patient population, directly
reimbursed by CAPITAL SALUD EPS.
- CAPITAL SALUD EPS is owned by
the City of Bogota and insures
more than 1.2 million people in and around the city, including more
than 280,000 active patients with chronic conditions including
pain, epilepsy, and mental health.
- Zerenia has already begun treating the first cohort of CAPITAL
SALUD´s patients with medical cannabis.
TORONTO, Jan. 9, 2023
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to pioneer the
medical cannabis market in LATAM by announcing that Zerenia has
signed a contract with insurance CAPITAL SALUD EPS, to provide
medical cannabis services and products to CAPITAL SALUD EPS patient
population and has already begun treating the first cohort of
patients. Under the contract, CAPITAL SALUD EPS patients will get
access to Khiron's products and clinical services fully reimbursed
by CAPITAL SALUD EPS.
In 2022, the Bogota City Council and the Bogota Mayor's office launched a first of its
kind initiative with the purpose of establishing the city as a
research, production, and commercialization hub for medical
cannabis for Colombia and
Latin America. As part of this
initiative, CAPITAL SALUD EPS - which is wholly owned by the
City of Bogota - has signed a
contract with Zerenia to provide "Integrative Health Services and
Pharmacotherapeutic Treatment with Medical Cannabis" to its patient
population.
City councilman Juan Baena, who
spearheaded the initiative comments: "This agreement by CAPITAL
SALUD EPS seeks the materialization of Agreement 831 that we
promoted at the Bogota City Council, with the objective of making
Bogota the medical cannabis hub of
the country"
Under the contract with CAPITAL SALUD EPS, Zerenia will provide
integrative health services and medical cannabis products to
patients diagnosed with chronic pain, mental health, neurological
conditions, and epilepsy, amongst others. With an annual budget of
more than CAD 500 million, 1.2
million insured individuals, and more than 280,000 patients
diagnosed with chronic conditions, CAPITAL SALUD EPS is the largest
public insurance company in Colombia.
Alvaro Torres, CEO of Khiron,
comments: "The city of Bogota has
embraced medical cannabis as a catalyst for social and economic
growth. We are honored that Zerenia was selected by CAPITAL SALUD
EPS to provide medical cannabis services and products to their
patients. Over the past 2 years, Zerenia has invested in expanding
its clinic locations across the city, generating proprietary
scientific evidence on the benefits of medical cannabis, and
delivering superior patient service quality to become the leaders
in medical cannabis in Colombia,
Latin America and Europe. We are thankful for the confidence
placed by CAPITAL SALUD on Zerenia, and with an installed capacity
of over 300,000 annual consultations, we are more than prepared to
service their patient base. We are convinced that we have created a
unique medical cannabis platform that other insurance companies in
Colombia and abroad will want to
offer to their patients to improve their quality of life."
About Khiron Life Sciences Corp.
Khiron is a leading
global medical cannabis company with core operations in
Latin America and Europe. Leveraging wholly owned medical health
clinics and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and focus on creating access to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Germany, the United
Kingdom, Switzerland,
Peru, and Brazil. The Company is led by its co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and board of directors.
Visit Khiron online at https://investors.khiron.ca.
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Statement Regarding Forward-Looking
Information
This press release may contain "forward-looking
information" within the meaning of applicable securities
legislation. All information contained herein that is not
historical in nature constitutes forward-looking information.
Forward-looking information contained in this news release may
include statements pertaining to the expected synergies and
benefits to the Company from the acquisition of the Target as well
as statements as to business strategy. Forward-looking information
and statements contained in this news release reflect management's
current beliefs and is based on information currently available and
on assumptions that management believes to be reasonable. These
assumptions include, but are not limited to, the expected benefits
to be realized by Khiron's business as a result of the acquisition
of the Target, and assumptions regarding market opportunities in
the jurisdictions in which the Company operates and where it seeks
to operate.
Although management believes that its expectations and
assumptions to be reasonable, forward-looking information is always
subject to known and unknown risks, uncertainties, and other
factors, many of which are beyond the control of management, that
may cause actual results to differ materially from those expressed
or implied in such forward-looking information. Such risks and
uncertainties include but are not limited to the following: general
economic conditions, adverse conditions in capital markets,
political uncertainties, counterparty risk, failing to obtain
required regulatory requirements and approvals, failure to maintain
required permits and licences, business integration risks, as well
as those other risk factors discussed in Khiron's most recent
annual information form which is available on Khiron's SEDAR
profile at www.sedar.com.
As a result of the foregoing and other risks and uncertainties,
readers are cautioned not to place undue reliance on
forward-looking information contained in this press release.
Readers are further cautioned that the foregoing risks and
uncertainties is not exhaustive, and there may be other risks and
uncertainties, presently unknown to management of the Company, that
may cause actual results to differ materially from those expressed
or implied in forward-looking statements contained in this press
release. The forward-looking information contained in this press
release is expressly qualified by this cautionary statement. Khiron
disclaims any intention to update or revise any forward-looking
information disclosed herein, whether as a result of new
information, future events or otherwise, except as required by
law.
NEITHER THE TSX VENTURE EXCHANGE, NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE), ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS PRESS RELEASE.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-wins-first-medical-cannabis-contract-with-colombias-largest-public-insurance-company-301716396.html
SOURCE Khiron Life Sciences Corp.